These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 34597912)
41. [Impact of minimal residual disease detection after treatment of multiple myeloma]. Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098 [TBL] [Abstract][Full Text] [Related]
42. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277 [TBL] [Abstract][Full Text] [Related]
43. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038 [TBL] [Abstract][Full Text] [Related]
44. Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time? Mina R; Bonello F; Oliva S Cancer J; 2021 May-Jun 01; 27(3):247-255. PubMed ID: 34549914 [TBL] [Abstract][Full Text] [Related]
56. Treatment for patients with newly diagnosed multiple myeloma in 2015. Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881 [TBL] [Abstract][Full Text] [Related]
57. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Kunacheewa C; Manasanch EE Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017 [TBL] [Abstract][Full Text] [Related]
58. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features. Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108 [TBL] [Abstract][Full Text] [Related]
59. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma. Cho H; Shin S; Chung H; Jang JE; Kim YR; Cheong JW; Min YH; Lee ST; Choi JR; Kim JS Br J Haematol; 2022 Aug; 198(3):503-514. PubMed ID: 35505579 [TBL] [Abstract][Full Text] [Related]
60. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Kunacheewa C; Manasanch EE Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]